Trial
NCT01816048
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
Millennium Pharmaceuticals, Inc.
Condition
Prostatic Neoplasms
Intervention
TAK-700
Why stopped
Study supporter (Takeda) ended study drug for prostate cancer; enrollment ended prematurely.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-09